Divis Laboratories Ltd News

Q1 results: Muthoot Finance, Divi's Labs, Nilkamal, and 30 more on Aug 1

Q1FY27 company results: Firms including Aarti Surfactants, Aditya Birla Lifestyle Brands, APL Apollo Tubes, and Utkarsh Small Finance Bank are also to release their April-June earnings today

Healthcare up for 4th straight month; Divis, Laurus, Torrent at new highs

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Sun Pharma, TVS Motor, Nestle, Divis among 11 BSE 500 stocks at new highs

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5%

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Stocks to buy: Ajit Mishra recommends CDSL, Divi's Labs, UltraTech Cement

On the overall market set-up, Ajit Mishra, SVP - Research at Religare Broking reckons to maintain a 'Buy-on-dips' approach, with a preference for relatively stronger stocks across sectors.

Divi's Labs rallies 3%, market cap nears ₹2 trillion; what's driving stock?

As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.

Divi's Labs slips 3% on margin worries; analysts positive on growth outlook

In the March quarter, Divi's Laboratories reported net profit at ₹751 crore, as compared to ₹662 crore a year ago, up 13.4 per cent year-on-year (Y-o-Y)

Nifty, Bank Nifty outlook; Coforge, Divi's Labs among top stock picks

Nifty outlook for today: Option data suggests a broader trading range in between 23,200 to 24,100 zones while an immediate range between 23,400 to 23,900 levels.

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Divi's Labs shares fall 3% on Q3 earnings miss; brokerages split on outlook

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,